Automate Your Wheel Strategy on CDTX
With Tiblio's Option Bot, you can configure your own wheel strategy including CDTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CDTX
- Rev/Share 0.0213
- Book/Share 9.9933
- PB 2.268
- Debt/Equity 0.0189
- CurrentRatio 3.8691
- ROIC -0.7284
- MktCap 293960517.0
- FreeCF/Share -13.5385
- PFCF -1.5315
- PE -1.778
- Debt/Assets 0.0139
- DivYield 0
- ROE -1.3107
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CDTX | Citizens JMP | -- | Mkt Outperform | -- | $46 | March 12, 2025 |
| Resumed | CDTX | Cantor Fitzgerald | -- | Overweight | -- | -- | Jan. 27, 2025 |
| Initiation | CDTX | RBC Capital Mkts | -- | Outperform | -- | $34 | Dec. 13, 2024 |
News
Cidara Therapeutics: All Stars Aligning In Favor Of CD388
Published: May 25, 2025 by: Seeking Alpha
Sentiment: Positive
Cidara Therapeutics' CD388 is a long-acting influenza antiviral aimed at providing universal protection with a single yearly dose for each flu season. In contrast to vaccines, CD388's efficacy is not dependent on circulating strains or on an intact patient immune system. CD388 is ideal for pandemic preparedness and for high-risk patients. Readout of a randomized ph2b trial of CD388 is expected by the end of June, with the potential to serve as one of the two needed trials for approval.
Read More
Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that Nicole Davarpanah, M.D., J.D. has been promoted to chief medical officer (CMO), and Corrina Pavetto has been promoted to senior vice president, clinical development, effective May 1, 2025.
Read More
Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that company management will participate in The Citizens Life Sciences Conference. Details are as follows: Event: The Citizens Life Sciences Conference Date: Wednesday, May 7, 2025 Time: 11:00 AM ET Format: Presentation Webcast: https://wsw.com/webcast/jmp65/cdtx/1686102 A replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com.
Read More
Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
About Cidara Therapeutics, Inc. (CDTX)
- IPO Date 2015-04-15
- Website https://www.cidara.com
- Industry Biotechnology
- CEO Dr. Jeffrey L. Stein Ph.D.
- Employees 38